Every round on record, with the sources behind each and the investors on them.
3 sources
Developing: it holds up against its sources so far, and firms up as more reporting lands.
The source names backers but does not identify a lead investor. Hugging Face is mentioned as Clement Delangue’s organization, not as an investor.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Seed [ HISTORY ]: An earlier round, from the company's own announcement, found while researching the company. Checked like any round, but not new, so it stays out of the daily feed and alerts; a date range shows it. | $28M | 2026-01-08 | Amplify Partners, Andreessen Horowitz, Zetta Venture Partners | No recent discussion |
3 sources [ DEVELOPING ] Developing: it holds up against its sources so far, and firms up as more reporting lands. read against 1 of 3 sources The source names backers but does not identify a lead investor. Hugging Face is mentioned as Clement Delangue’s organization, not as an investor. | ||||
Boltz builds AI models, software, and infrastructure that help pharmaceutical and biotech scientists design small molecules and biologics with fewer experiments.
Drug discovery is constrained by costly, slow physical experiments, while Boltz says its open models have reached more than 100,000 scientists across top pharmaceutical companies and thousands of biotechs. Its $110M Series A, following the $28M seed, funds the bet that open biomolecular models combined with a usage-based platform can move more screening and molecular design onto the computer, and the investor announcement reports roughly 50-fold growth in weekly molecular-token consumption by paying customers over four months.
Checked against 8 sources yesterday
Also named as backers in company research: Bessemer Venture Partners